FDA gave go ahead for AFFY too and look what just happened.
PSDV already at 2.30!! Wow!
trend in cancer care is that both female patients and oncologists are opting for safer treatments with lesser side effects, look it up.
will be low rev generator for Roche, lessor for Immogen.
PSDV is soaring, thank you very much!!!